7 Billion RMB Market Opportunity: Who Will Win the First Generic Approval for Topiramate Oral Solution?

Jun 16, 2025 07:31 CST Updated 07:31

Johnson & Johnson

Medical Device R&D and Manufacturer

On June 12, the CDE website accepted Shandong Lukang & JIUDIAN PHARMACEUTICAL.ofTopiramate Oral SolutionClass 3 generic drug marketing application. The original research drugThe manufacturer is Johnson & Johnson.Capsules in 201Obtained in 4 yearsApproved for marketing by the NMPA,Tablets in 2015 YearsEntering China, for the treatment of epilepsyTherapy.

Topiramate exerts its therapeutic effects through a triple mechanism: blocking sodium channels to inhibit abnormal discharges, enhancing GABA-mediated neural inhibition, and antagonizing AMPA receptors to reduce glutamate excitability. The drug has been approved globally for various indications, including multiple types of epilepsy (such as partial seizures, tonic-clonic seizures, and Lennox-Gastaut syndrome) as well as the prevention and treatment of migraines, providing a comprehensive treatment strategy for neurological disorders with its multi-target properties.

Topiramate Structural Information

Data Source: Pharma Data - Structural Information

Currently, epilepsy is the only approved indication in China. As of 2024, the global epilepsy drug market size has reached 4.278 billion US dollars. Although it experienced a declining trend since 2020, it has shown a relatively stable situation in the past five years. According to the data from PharmaDJ, the market size of epilepsy treatment in China has approached 7 billion RMB, with the medical institution channel (including hospitals at all levels and grassroots medical institutions) taking the dominant position, accounting for 68% of the market share. In the retail terminal, physical pharmacies are the main sales channel, and the market size of offline pharmacies for this indication is about 1.5 billion RMB, forming a three-dimensional market pattern of "medical end leading, retail end supplementing."

Global Epilepsy Market Situation (Million USD)

Data Source: Pharma Data - Indications

In the first three quarters of 2024, Topiramate achieved sales of 123 million RMB in the Chinese market, with an estimated total annual sales to exceed 180 million RMB, accounting for approximately 2.6% of the total Chinese epilepsy drug market. Topiramate holds a certain market share in the field of epilepsy treatment in China, but its overall market penetration still has significant room for growth.

Topiramate Sales in China

Data Source: PharmaBlock Data - Sales in China

Looking at the competitive landscape of topiramate products,Oral administrationSolution Agent in ChinaNot yet obtained marketing authorization.In the generic drug sector, apart from Shandong Lukang & JIUDIAN PHARMACEUTICAL, the generic applications for topiramate oral solution from four other companies, including Huayi Pharmaceuticals and Renhey Yikang, are currently under review. Market expectations suggest that the first generic company for this formulation will be announced within 2025, which will have a significant impact on the market landscape of this niche.

Competitive Landscape of Topiramate Oral Solution Generics

Data Source: PharmaBlock Data - Generic Drugs

Other dosage forms of topiramate also includeTablets, Capsules, and Extended-Release CapsulesAmong them, the market for topiramate capsules is highly concentrated, with only the original research company Johnson & Johnson having been approved for import in 2014. No domestic companies have submitted related generic applications so far. Similarly, extended-release topiramate capsules have not been approved in China; Ambit Pharmaceuticals was the only company to submit a generic application in 2022, but it was not approved in 2023. In contrast, the competition in the topiramate tablet market is the most active, with four companies, including the original research company Johnson & Johnson, having obtained marketing approval. Chinese generic drug manufacturers Huahai Pharmaceuticals, Heyuan Pharmaceuticals, and Rizhongtian Pharmaceuticals have successfully been approved to enter the market. Meanwhile, three companies—Xinshidai Pharmaceuticals, Ideal Pharmaceuticals, and Keruide Pharmaceuticals—are actively promoting their generic topiramate tablet applications, indicating that competition in this segment will further intensify.

Competition Situation of Topiramate Tablets Generic Drugs

Data Source: PharmaBlock Data - Generic Drugs

With the deepening of multi-dosage form layout and the intensification of generic drug competition, this field will usher in a more diversified market pattern.

Lilly Bets $870 Million on Long-Acting Injectable, Will the Diabetes Battlefield Welcome a "Liquid Crystal Bomb"?
Potential First-in-Class! Merck's Oral PCSK9 Inhibitor Phase III Study Successful
U.S. Public Health "Slimming" for Survival: CDC Vaccine Team Fully Disbanded, FDA Introduces AI Review, Budget Gaps Force Reform